Attached files
| file | filename |
|---|---|
| EX-10.1 - PACIFICHEALTH LABORATORIES INC | v210339_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 4, 2011
PACIFICHEALTH
LABORATORIES, INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
000-23495
|
22-3367588
|
|
(State
or Other Jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
Incorporation)
|
File
Number)
|
Identification
Number)
|
|
100
Matawan Road, Suite 150, Matawan, NJ
|
07747-3913
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code: (732) 739-2900
N/A
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
1.01
|
Entry
into a Material Definitive
Agreement.
|
On February 4, 2011, PacificHealth
Laboratories, Inc. (the “Registrant”) entered into a
consulting agreement (the “Agreement”) with Signal
Nutrition LLC (“Signal”). Robert
Portman, a Director of the Registrant is the sole member of Signal. Under the
terms of the Agreement, Signal will work with outside researchers on behalf of
the Registrant, assist the Registrant in developing new products, and formulate
sales and marketing plans. The Agreement has an indefinite term with
an option by either party to terminate the agreement on thirty (30) days
notice. The Registrant will pay Signal a fee of $16,000 per month,
commencing March 1, 2011, during the term of the Agreement.
The foregoing description is a summary
and is qualified in its entirety by a copy of the Agreement attached as Exhibit
10.1 hereto and incorporated by reference herein.
|
Item
9.01.
|
Financial
Statements and Exhibits
|
|
(d)
|
Exhibits
|
10.1 Consulting
Agreement dated February 4, 2011 by and between PacificHealth Laboratories, Inc.
and Signal Nutrition LLC.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
| PACIFICHEALTH LABORATORIES, INC. | |||
|
Dated: February
8, 2011
|
By:
|
/s/ Stephen P. Kuchen | |
| Stephen P. Kuchen | |||
| Chief Financial Officer | |||
2